Subtype and pathway specific responses to anticancer compounds in breast cancer.
about
Cancer pharmacogenomics: strategies and challengesThe Cancer Genome Atlas Pan-Cancer analysis projectPathway Analysis: State of the ArtLeveraging big data to transform target selection and drug discoveryTumor-Derived Cell Lines as Molecular Models of Cancer PharmacogenomicsIn vitro human cell line models to predict clinical response to anticancer drugsToward precision medicine of breast cancerUsing Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyPatient-derived tumour xenografts for breast cancer drug discoveryHER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancerCancer Genome Atlas Pan-cancer Analysis ProjectMachine learning prediction of cancer cell sensitivity to drugs based on genomic and chemical propertiesHigh-throughput 3D screening reveals differences in drug sensitivities between culture models of JIMT1 breast cancer cellsWidespread molecular patterns associated with drug sensitivity in breast cancer cell lines, with implications for human tumorsDo breast cancer cell lines provide a relevant model of the patient tumor methylome?Conceptualizing cancer drugs as classifiersContext Sensitive Modeling of Cancer Drug SensitivityDeciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin ActionPathway-Based Genomics Prediction using Generalized Elastic NetA Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer CompoundsTargeting the adaptability of heterogeneous aneuploidsA community effort to assess and improve drug sensitivity prediction algorithms.Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies.Computational solutions for omics data.Using large-scale molecular data sets to improve breast cancer treatment.Gene-expression data integration to squamous cell lung cancer subtypes reveals drug sensitivityExploring TCGA Pan-Cancer data at the UCSC Cancer Genomics Browser.Lean Big Data integration in systems biology and systems pharmacology.Disentangling multidimensional spatio-temporal data into their common and aberrant responsesPublisher’s Note:Abstraction for data integration:Fusing mammalian molecular, cellular and phenotype big datasets for better knowledge extraction.dcVar: a method for identifying common variants that modulate differential correlation structures in gene expression data.Integrative "omic" analysis for tamoxifen sensitivity through cell based models.Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithmPatterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.A personalized committee classification approach to improving prediction of breast cancer metastasis.Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.
P2860
Q24289309-453721D1-9B6B-40F4-9EA0-958365514481Q24606808-C56CA564-3F16-4DA7-A7FD-BA3E5FA4770BQ26770725-A38EB6BE-EA05-44FB-8988-37C108147F56Q26776403-D2C08335-8B17-484C-961F-F845EF19AFE7Q26801410-C9152CBA-E4DD-4889-8D50-B6DC06484FDAQ27000665-327180BD-C0F2-4ADA-9A10-B45FF4A82C29Q28073967-931945E6-DE64-4A47-B90D-2907185A45CEQ28076097-2F8B2D01-EE17-4FAA-9992-AC575CA00928Q28080046-040D1A91-5005-4623-9D74-914C39F70123Q28085413-B83799FE-B3BC-4DAD-BAD5-189406FBD84CQ28085552-43079E7D-8120-4337-B02D-BCED8F0EFF5BQ28487333-0C201AF1-E2BF-4F66-BC3A-59FF0475644CQ28534624-F115E9DD-BA51-425A-A0BC-041A7CC0BF10Q28538033-F2FD6949-DE1C-48F9-8CBD-E5704C10D757Q28542556-BFB79E31-45A2-4DB6-AF97-C71A57037A18Q28543160-1BBE13FC-8F08-4B97-A5F5-F9CAA752033EQ28547285-6579BD72-964C-4C8B-A67B-273013A02C79Q28548411-B7DFAEAF-B34C-44E4-9AF0-18B3D73F48F1Q28550614-1BD07100-2B97-474D-8BDE-3681F6663F67Q28598343-AB973758-09DC-4A1B-9ECA-C9AC5A5F83FFQ28649939-0D1C715C-EE22-41BF-AC58-50225EF3250EQ30371323-575CF89B-8980-4370-8593-0D1B07AB6989Q30436867-70A54FEE-083D-490C-B398-6ED1277BE9B6Q30617899-364937EF-ACE8-4429-A6C5-4B7F06371D4FQ30656126-2526ADA8-255D-4948-B583-F019E30EA9D1Q30664828-957BAC3F-3150-42F0-AF5B-7BAA215E40C4Q30671000-E0D07A1D-7874-4F93-B377-2F528932575FQ30841748-5F5D1D87-8AB3-44D5-9C13-9F1D304DE1B8Q30938497-4CC43967-AE67-4D36-A850-EA8B23EBBE17Q30976077-C1B55EAE-D04C-4154-BD56-7FF23869AD69Q31018233-8BDC15B1-D2E3-416E-A9E7-51C497953362Q31156438-DBDF44A9-781D-441A-A23D-2B750A974CF3Q33556468-1B2DA5D8-2043-49A5-9FED-90887276A476Q33601653-1222D475-0521-4B94-9DB5-31555432F61AQ33605906-9AD34635-0ACD-426D-9A12-56A5AC5B3581Q33623555-A5D7B037-D28E-4DCC-A73D-9C3E697FF3CEQ33731278-CB3C97EE-4548-4560-9208-CC65265780E4Q33731365-386413DD-9BD6-4700-BECB-92396576B39DQ33807643-E3237D41-75DE-40C1-8C71-E4FB0344F2E4Q33835127-2E569DF4-07F7-41A4-9537-4FD0DEC606E8
P2860
Subtype and pathway specific responses to anticancer compounds in breast cancer.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@ast
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@en
type
label
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@ast
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@en
prefLabel
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@ast
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@en
P2093
P2860
P50
P356
P1476
Subtype and pathway specific responses to anticancer compounds in breast cancer.
@en
P2093
Andrea Dueregger
Bryan T Hennessy
Denise M Wolf
Elizabeth Purdom
Eric A Collisson
Frances Tong
François Pepin
Gordon B Mills
Heidi S Feiler
Henrik Bengtsson
P2860
P304
P356
10.1073/PNAS.1018854108
P407
P577
2011-10-14T00:00:00Z